Abstract
Purpose. The aim of this study was to evaluate the ability of long-circulating PEGylated cyanoacrylate nanoparticles to diffuse into the brain tissue.
Methods. Biodistribution profiles and brain concentrations of [14C]-radiolabeled PEG-PHDCA, polysorbate 80 or poloxamine 908-coated PHDCA nanoparticles, and uncoated PHDCA nanoparticles were determined by radioactivity counting after intravenous administration in mice and rats. In addition, the integrity of the blood-brain barrier (BBB) after nanoparticles administration was evaluated by in vivo quantification of the diffusion of [14C]-sucrose into the brain. The location of fluorescent nanoparticles in the brain was also investigated by epi-fluorescent microscopy.
Results. Based on their long-circulating characteristics, PEGylated PHDCA nanoparticles penetrated into the brain to a larger extent than all the other tested formulations. Particles were localized in the ependymal cells of the choroid plexuses, in the epithelial cells of pia mater and ventricles, and to a lower extent in the capillary endothelial cells of BBB. These phenomena occurred without any modification of BBB permeability whereas polysorbate 80-coated nanoparticles owed, in part, their efficacy to BBB permeabilization induced by the surfactant. Poloxamine 908-coated nanoparticles failed to increase brain concentration probably because of their inability to interact with cells.
Conclusions. This study proposes PEGylated poly (cyanoacrylate) nanoparticles as a new brain delivery system and highlights two requirements to design adequate delivery systems for such a purpose: a) long-circulating properties of the carrier, and b) appropriate surface characteristics to allow interactions with BBB endothelial cells.
Similar content being viewed by others
REFERENCES
S. I. Rapoport. Blood-Brain Barrier in Physiology and Medicine, Raven Press, New York, 1976.
D. J. Begley. The blood-brain barrier: principles for targeting peptides and drugs to the central nervous system. J. Pharm. Pharmacol. 48:136-146 (1996).
R. A. Kroll and E. A. Neuwelt. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery 42:1083-1099 (1998).
W. M. Pardridge. Vector mediated drug delivery the brain. Adv. Drug Deliv. Rev. 36:299-321 (1999).
J. Huwyler, D. Wu, and W. M. Pardridge. Brain drug delivery of small molecules using immunoliposomes. Proc. Natl. Acad. Sci. USA 93:14164-14169 (1996).
M. Naoi and Y. Eto. Liposome targeting to mouse brain: mannose as a recognition marker. Biochem. Biophys. Res. Commun. 153:1038-1044 (1988).
P. Couvreur, C. Dubernet, and F. Puisieux. Controlled drug delivery with nanoparticles: Current possibilities and future trends. Eur. J. Pharm. Biopharm. 41:2-13 (1995).
S. D. Troster, U. Müller, and J. Kreuter. Modification of the body distribution of poly(methylmethacrylate) nanoparticles in rats by coating with surfactants. Int. J. Pharm. 61:85-100 (1990).
S. M. Moghimi. Mechanisms regulating body distribution of nanospheres conditioned with pluronic and tetronic block copolymers. Adv. Drug Deliv. Rev. 16:183-193 (1995).
S. Stolnik, L. Illum, and S. S. Davis. Long circulating microparticulate drug carriers. Adv. Drug Deliv. Rev. 16:195-214 (1995).
R. Gref, Y. Minamitake, M. T. Peracchia, V. S. Trebetskoy, V. P. Torchilin, and R. Langer. Biodegradable long-circulating polymeric nanospheres. Science 263:1600-1603 (1994).
M. T. Peracchia, E. Fattal, D. Desmaële, M. Besnard, J. P. Noël, J. M. Gomis, M. Appel, J. D'Angelo, and P. Couvreur. Stealth® PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting. J. Control. Release 60:121-128 (1999).
J. Kreuter, R. N. Alyautdin, D. A. Kharkevich, and A. A. Ivanov. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res. 674:171-174 (1995).
U. Schröder and B. A. Sabel. Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections. Brain Res. 710:121-124 (1996).
R. N. Alyautdin, V. E. Petrov, K. Langer, A. Berthold, D. A. Kharkevich, and J. Kreuter. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm. Res. 14:325-328 (1997).
R. N. Alyautdin, E. B. Tezikov, P. Ramges, D. A. Kharkebich, D. J. Begley, and J. Kreuter. Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polyisobutylcyanoacrylate nanoparticles: an in situ brain perfusion study. J. Microencapsul. 15:67-74 (1998).
A. Friese, E. Seiller, G. Quack, B. Lorenz, and J. Kreuter. Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. Eur. J. Pharm. Biopharm. 49:103-109 (2000).
A. E. Gulyaev, S. E. Gelperina, I. N. Skidan, A. S. Antropov, G. Y. Kivman, and J. Kreuter. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm. Res. 16:1564-1569 (1999).
J. C. Olivier, L. Fenart, R. Chauvet, C. Pariat, R. Cecchelli, and W. Couet. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharm. Res. 16:1836-1842 (1999).
I. Brigger, P. Chaminade, D. Desmaële, M. T. Peracchia, J. D'Angelo, R. Gurny, M. Renoir, and P. Couvreur. Near infrared with principal component analysis as a novel analytical approach for nanoparticle technology. Pharm. Res. 17:1124-1132 (2000).
H. Fessi, F. Puisieux, J. P. Devissaguet, N. Ammoury, and S. Benita. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int. J. Pharm. 55:R1-R4 (1989).
L. Illum, I. M. Hunneyball, and S. S. Davis. The effect of hydrophilic coatings on the uptake of colloidal particles by the liver and peritoneal macrophages. Int. J. Pharm. 29:53-67 (1986).
M. T. Peracchia, C. Vauthier, D. Desmaële, A. Gulik, J. C. Dedieu, M. Demoy, J. D'Angelo, and P. Couvreur. Pegylated nanoparticles from a novel methoxypolyethylene glycol cyanoacrylate-hexadecyl cyanoacrylate amphiphilic copolymer. Pharm. Res. 15:550-556 (1998).
K. Ohno, K. D. Pettigrew, and S. I. Rapoport. Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. Am. J. Physiol. 235:H299-H307 (1978).
R. D. Broadwell and M. V. Sofroniew. Serum proteins bypass the blood-brain barrier for extracellular entry to the central nervous system. Exp. Neurol. 120:245-263 (1993).
J. C. Neal, S. Stolnik, E. Schacht, E. R. Kenawy, M. C. Garnett, S. S. Davis, and L. Illum. In vitro displacement by rat serum of adsorbed radiolabeled poloxamer and poloxamine copolymers from model and biodegradable nanospheres. J. Pharm. Sci. 87: 1242-1248 (1998).
H. Harashima, S. Komatsu, S. Kojima, C. Yanagi, Y. Morioka, M. Naito and H. Kiwada. Species difference in the disposition of liposomes among mice, rats, and rabbits: allometric relationship and species dependent hepatic uptake mechanism. Pharm. Res. 13:1049-1054 (1996).
M. Demoy, J. P. Andreux, C. Weingarten, B. Gaouritin, V. Guilloux, and P. Couvreur. Spleen capture of nanoparticles: influence of animal species and surface characteristics. Pharm. Res. 16:37-41 (1999).
S. I. Rapoport, W. R. Fredericks, K. Ohno, and K. D. Petrigrew. Quantitative aspects of reversible osmotic opening of the blood-brain barrier. Am. J. Physiol. 238:R421-R431 (1980).
S. M. Moghimi, I. S. Muir, L. Illum, S. S. Davis, and V. Kolb-Bachofen. Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum. Biochim. Biophys. Acta 1179:157-165 (1993).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Calvo, P., Gouritin, B., Chacun, H. et al. Long-Circulating PEGylated Polycyanoacrylate Nanoparticles as New Drug Carrier for Brain Delivery. Pharm Res 18, 1157–1166 (2001). https://doi.org/10.1023/A:1010931127745
Issue Date:
DOI: https://doi.org/10.1023/A:1010931127745